findmyKOL
Clinical trialNCT03587194CompletedPhase 4Interventional

Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis

SponsorPsoriasis Treatment Center of Central New JerseyEnrollment50Psoriasis
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Add-on Enstilar to Otezla therapy.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Psoriasis Treatment Center of Central New Jersey

    East Windsor, New Jersey, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Apremilast →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
23 Jul 2018
Primary completion
1 Jul 2019
Completion
1 Jul 2019
Last update posted
16 Apr 2024
Registered enrollment
50
Registry id
NCT03587194
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.